BCM
ONCE

Bayesian Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bayesian Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,442
Closed -$574K – 797
2017
Q3 		$574K Buy
+6,442
New +$489K 0.14% 242

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bayesian Capital Management's ONCE Position: Q4 2017 in Review

Bayesian Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2017, closing a stake of 6,442 shares — an estimated $574K sold.

Bayesian Capital Management first reported a position in ONCE in Q3 2017 and held it in 1 quarter. The position peaked at $574K in Q3 2017. 160 funds tracked by Wall St. Rank hold ONCE as of Q4 2017.

  • Bayesian Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 6,442 Spark Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $574K.
  • Bayesian Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Bayesian Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $574K in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Bayesian Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.